Linnea Haeggblom

Linnea Haeggblom is a Senior Scientist currently at Amgen since December 2023, with extensive experience in translational biomarker development in the myeloid immuno-oncology space from a previous role at Pionyr Immunotherapeutics. Linnea's expertise includes the development of tissue-based assays and antibody screenings, utilizing advanced technologies such as chromogenic IHC/ISH and high-plex IF, alongside mastering image analysis tools to study tumor microenvironments. Prior experience includes positions at Merck and Karolinska Institutet, focusing on tissue profiling and HPV-related cancer research, as well as a significant academic background with a PhD in Medical Science from Karolinska Institutet. Additional experience includes internships and roles that span research, ethics, and education, highlighting a comprehensive skill set in medical science and research methodologies.